Kymera Therapeutics (NASDAQ: KYMR) revenue
Kymera Therapeutics reported revenue of $39.2m for fiscal 2025, 16.7% less than in fiscal 2024 ($47.1m). Since fiscal 2019 its revenue has grown by 1,236.4%, an average growth of 54.0% a year.
Kymera Therapeutics's revenue has fallen for 2 years in a row, and its best year of the last 7 was fiscal 2023. The biggest drop was in fiscal 2024, −40.1%.
Embed this chart
Copy this code into your website or blog. The chart updates with each new annual report.
Revenue by fiscal year
| Fiscal year | Revenue | Change | Operating profit | Operating margin |
|---|---|---|---|---|
| 2025 | $39.2m | −16.7% | −$349.4m | −891.1% |
| 2024 | $47.1m | −40.1% | −$261.6m | −555.8% |
| 2023 | $78.6m | +67.8% | −$165.5m | −210.6% |
| 2022 | $46.8m | −35.7% | −$161.3m | −344.4% |
| 2021 | $72.8m | +114.0% | −$100.5m | −138.0% |
| 2020 | $34.0m | +1,060.0% | −$46.3m | −136.1% |
| 2019 | $2.9m | — | −$42.2m | −1,438.5% |
The change compares each fiscal year with the one before. Operating margin is operating profit over revenue from the same filing. Figures are in millions of US dollars, except per-share amounts.
Kymera Therapeutics revenue compared with its sector
By revenue for its latest fiscal year, Kymera Therapeutics ranks 340th of the 422 US health care companies with a page on Celsmar. The sector median grew 11.7% in its latest fiscal year; Kymera Therapeutics, −16.7%.
| Rank | Company | Revenue | Revenue growth |
|---|---|---|---|
| 338th | Alpha Teknova | $40.5m | 7.4% |
| 339th | Voyager Therapeutics | $40.4m | −49.5% |
| 340th | Kymera Therapeutics | $39.2m | −16.7% |
| 341st | Utah Medical Products | $38.5m | −5.8% |
| 342nd | ClearPoint Neuro | $37.0m | 17.8% |
Each amount is in the currency the company reports in; the rank converts them to US dollars at the 16 November 2026 exchange rate. The rest are in US health care stocks.
Questions about the revenue of Kymera Therapeutics
- How much revenue did Kymera Therapeutics make in fiscal 2025?
- Kymera Therapeutics reported revenue of $39.2m for fiscal 2025, compared with $47.1m in fiscal 2024.
- How much has the revenue of Kymera Therapeutics grown?
- Between fiscal 2019 and fiscal 2025 it went from $2.9m to $39.2m: 1,236.4% more, an average growth of 54.0% a year.
- What was the best year for revenue at Kymera Therapeutics?
- Of its last 7 fiscal years, fiscal 2023, with $78.6m.
- Where does Kymera Therapeutics rank in its sector by revenue?
- It ranks 340th of the 422 US health care companies with a page on Celsmar, by revenue for its latest fiscal year.
- Where do the figures for Kymera Therapeutics come from?
- From the annual report (Form 10-K) that Kymera Therapeutics files with the SEC, the US securities regulator. Each fiscal year links to its filing.
Where each figure comes from
From the annual report (Form 10-K) that Kymera Therapeutics files with the SEC. The filing for each fiscal year: 2025 · 2024 · 2023 · 2022 · 2021 · 2020 · 2019. More on Kymera Therapeutics: the Kymera Therapeutics page · annual accounts · net income · insider transactions.
Information prepared from the accounts the company files with the regulator, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.